Please assess the completion status of the following clinical trial:

Trial Title: A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 16.0

Eligibility Criteria:
Have participated in previous studies (JAHL, JAHM and JAIY) and met specific completion requirements for those studies, and do not meet any of the following Exclusions:~Exclusion Criteria:~* Had investigational product permanently discontinued at any time during a previous Baricitinib study.~* Had temporary investigational product interruption continue at the final study visit of a previous Baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study~OR~Have not participated in previous studies (JAHL, JAHM and JAIY) and satisfy the following criteria:~Inclusion Criteria:~* Have been diagnosed with moderate to severe Atopic Dermatitis for at least 12 months.~* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.~* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).~* Agree to use emollients daily.~Exclusion Criteria:~* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.~* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.~* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.~* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).~* Have been treated with the following therapies:~  * Monoclonal antibody for less than 5 half-lives prior to randomization.~ * Received prior treatment with any oral Janus kinase (JAK) inhibitor.~ * Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.~ * Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.~* Have high blood pressure characterized by a repeated systolic blood pressure \>160 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 mm Hg.~* Have had major surgery within the past eight weeks or are planning major surgery during the study.~* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.~* Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.~* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.~* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.~* Have specific laboratory abnormalities.~* Have received certain treatments that are contraindicated.~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Responders and Partial Responders (RPR)-Placebo (Type: PLACEBO_COMPARATOR): Responders or partial responders (RPR) \[Investigator's Global Assessment (IGA) of (0,1, or 2) at entry to study JAHN and never rescued in originating study\] participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive placebo orally.
- RPR-Bari 1-milligram (mg) (Type: EXPERIMENTAL): RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM were assigned to remain in this arm to receive Baricitinib 1 mg orally.
- RPR-Bari 2-mg (Type: EXPERIMENTAL): RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 2 mg orally.
- RPR-Bari 4-mg (Type: EXPERIMENTAL): RPR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY were assigned to remain in this arm to receive Baricitinib 4 mg orally.
- Non-responders (NR): Bari 1 mg to 2 mg (Type: EXPERIMENTAL): Non-responder (NR) \[those not meeting definition of RPR\] participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
- NR: Bari 1 mg to 4 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM who received Baricitinib 1 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
- NR: Bari 2 mg to 2 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 2 mg orally.
- NR: Bari 2 mg to 4 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 2 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
- NR: Bari 4 mg to 4 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received Baricitinib 4 mg and were re-randomized to this arm to receive Baricitinib 4 mg orally.
- NR: Placebo to Bari 2 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 2 mg orally.
- NR: Placebo to Bari 4 mg (Type: EXPERIMENTAL): NR participants from previous Baricitinib monotherapy studies-JAHL and JAHM and combination therapy study-JAIY who received placebo and were re-randomized to this arm to receive Baricitinib 4 mg orally.
- Placebo (Type: PLACEBO_COMPARATOR): Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive placebo orally.
- Bari 1 mg (Type: EXPERIMENTAL): Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) were randomized or assigned to this arm to receive Baricitinib 1 mg orally.
- Bari 2 mg (Type: EXPERIMENTAL): Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 2 mg orally.
- Bari 4 mg (Type: EXPERIMENTAL): Participants from previous Baricitinib monotherapy studies (JAHL, JAHM) and combination therapy study (JAIY) were randomized or assigned to this arm to receive Baricitinib 4 mg orally.
- Bari 2-mg Open-Label Addendum (Type: EXPERIMENTAL): Participants were directly enrolled to this open-label arm to receive Baricitinib 2-mg orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete